Kinney Gene G. sold (to issuer) $719K of PRTA
Kinney Gene G. (President and CEO) sold (to issuer) 84,000 shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $8.56 ($0.72M total) on 2026-07-28.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO’s sale to the issuer of 84,000 shares at $8.56/share on 2026-07-28, reported via a Form 4 filed 2026-07-30.
Market read
Traders may monitor insider selling as a sentiment input, but this filing alone does not provide a new fundamental catalyst.
What to watch
The article does not state whether the sale was part of a broader compensation or buyback program, nor does it provide context on prior insider activity or total holdings changes over time.
Background
The article is an SEC Form 4 insider transaction disclosure for Prothena Corp Public Ltd Co.
Ticker impact
Prothena CEO Kinney Gene G. sold 84,000 shares to the issuer at $8.56/share, leaving 68,793 shares after the Form 4.
Likely limited near-term impact; any effect is more signaling than fundamental.
The filing is a Form 4 insider transaction with no 10b5-1 plan and no accompanying company guidance, deal, or regulatory action in the text.
Market effects
Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or clinical changes.
None indicated.
None indicated.
Counterpoint
Even without a 10b5-1 plan, a sale to the issuer can reflect liquidity needs rather than bearish expectations, so the market may ignore it.
Key entities
- issuerPROTHENA CORP PUBLIC LTD CO
Subject of the Form 4 insider transaction disclosure (PRTA).
- insiderKinney Gene G.
President and CEO who sold shares to the issuer.
